Familial Mediterranean fever (FMF)-response to TNF-blockers used for treatment of FMF patients with concurrent inflammatory diseases
| Autor: | Soad Hajyahia, Ilan Ben-Zvi, Avi Livneh, Merav Lidar |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
030203 arthritis & rheumatology
medicine.medical_specialty business.industry Tumor Necrosis Factor-alpha Interleukin Familial Mediterranean fever Disease medicine.disease Familial Mediterranean Fever Pathogenesis 03 medical and health sciences 0302 clinical medicine Rheumatology Internal medicine medicine Humans Tumor necrosis factor alpha Tumor Necrosis Factor Inhibitors 030212 general & internal medicine Autoinflammatory disease business Colchicine Interleukin-1 |
| Zdroj: | Joint bone spine. 88(5) |
| ISSN: | 1778-7254 |
| Popis: | Objective Familial Mediterranean fever (FMF) is the most common interleukin 1 (IL-1)-driven monogenic autoinflammatory disease. Yet published data also suggest that tumor necrosis factor (TNF) may have a role in the pathogenesis of FMF and may serve as a target for treatment. In the present study we evaluate this hypothesis. Methods To this goal, we studied the incidental effect on FMF of TNF-directed treatment, administered to colchicine-refractory FMF patients for the management of a concurrent inflammatory disease. The rates of FMF patients and of treatments with complete or nearly complete FMF response were determined, based on the number of FMF attacks during TNF-blocker exposures. The possible effect of various FMF and non-FMF features on the outcome was determined using comparative analysis. Patients were identified and data were retrieved using electronic files from the FMF clinic. Results Twenty-six patients were identified, each receiving ≥ 1 of four TNF-blockers for a mean duration of 27.6 ± 16.4 months. The TNF-blockers were found to induce complete or nearly complete FMF response in 10 (38.5%) of the patients, and in 13 of 50 (26%) exposures. No clinical, genetic, demographic, or therapeutic feature could predict which FMF patient would respond favorably to TNF-blocker therapy. Conclusion This study suggests that TNF-blockers may be beneficial for a small proportion of colchicine-resistant FMF patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect